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Vagus Nerve Stimulation for Treatment-Resistant
Depression: A Randomized, Controlled Acute
Phase Trial
A. John Rush, Lauren B. Marangell, Harold A. Sackeim, Mark S. George, Stephen K. Brannan, Sonia M. Davis,
Robert Howland, Mitchel A. Kling, Barry R. Rittberg, William J. Burke, Mark H. Rapaport, John Zajecka,
Andrew A. Nierenberg, Mustafa M. Husain, David Ginsberg, and Robert G. Cooke
Background: Vagus nerve stimulation (VNS) alters both concentrations of neurotransmitters or their metabolites and functional
activity of central nervous system regions dysregulated in mood disorders. An open trial has suggested efficacy.
Methods: This 10-week, acute, randomized, controlled, masked trial compared adjunctive VNS with sham treatment in 235 outpatients
with nonpsychotic major depressive disorder (n ⫽ 210) or nonpsychotic, depressed phase, bipolar disorder (n ⫽ 25). In the current episode,
participants had not responded adequately to between two and six research-qualified medication trials. A two-week, single-blind recovery
period (no stimulation) and then 10 weeks of masked active or sham VNS followed implantation. Medications were kept stable. Primary
efficacy outcome among 222 evaluable participants was based on response rates (ⱖ50% reduction from baseline on the 24-item Hamilton
Rating Scale for Depression [HRSD24]).
Results: At 10-weeks, HRSD24 response rates were 15.2% for the active (n ⫽ 112) and 10.0% for the sham (n ⫽ 110) groups (p ⫽ .251,
last observation carried forward [LOCF]). Response rates with a secondary outcome, the Inventory of Depressive Symptomatology –
Self-Report (IDS-SR30), were 17.0% (active) and 7.3% (sham) (p ⫽ .032, LOCF). VNS was well tolerated; 1% (3/235) left the study
because of adverse events.
Conclusions: This study did not yield definitive evidence of short-term efficacy for adjunctive VNS in treatment-resistant depression.
Key Words: Vagus nerve stimulation (VNS), major depressive disorder, bipolar disorder, treatment-resistant depression (TRD), clinical
trial, efficacy, side effects

T

he Vagus Nerve Stimulation (VNS) Therapy System has
been shown to reduce the frequency of seizures among
patients with pharmacoresistant epilepsy (Ben-Menachem et al 1994; Handforth et al 1998; Vagus Nerve Stimulation Study Group 1995). Over 29,000 patients with epilepsy
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have been implanted with the VNS device (data on file with
Cyberonics), and few clinically significant adverse events
(AEs) have been noted (Schachter and Saper 1998).
The rationale for evaluating the antidepressant efficacy of
VNS has been reviewed elsewhere (George et al 2000; Rush et
al 2000b). In brief, VNS alters the cerebrospinal fluid (CSF)
concentrations of neurotransmitters or their metabolites (e.g.,
increased gamma-aminobutyric acid (GABA), increased 5-hydroxyindoleacetic acid (5H1AA), increased homovanillic acid
(Carpenter et al 2004; Hammond et al 1992; Ben-Menachem et
al 1995) in animal and human studies. VNS also alters the
functional activity of CNS regions, (e.g., orbital frontal cortex,
insula, thalamus, hypothalamus, cingulate, and hippocampus)
dysregulated in mood disorders (Chae et al 2003; Henry et al
1998). Third, certain anticonvulsants (and, therefore, potentially VNS) have therapeutic value in mood disorders. Finally,
epilepsy patients who have received VNS have shown improvement in depressive symptoms independent of the degree of seizure control (Elger et al 2000; Harden et al 2000).
A 10-week acute phase, open trial (Sackeim et al 2001b)
found a 30.5% response rate (i.e., ⱖ50% reduction in HRSD28
scores) among outpatients (n ⫽ 59) with treatment-resistant,
nonpsychotic major depressive episodes (MDEs). Naturalistic
follow-up of these 59 patients revealed 44% response and 27%
remission rates (LOCF) after 1 year of VNS, and 44% response
and 22% remission rates (LOCF) after 2 years of VNS (Rush et
al 2003a). Given the severity of the mood disorder and the
degree of prior treatment resistance of the patients in the pilot
study, the acute and 1-year follow-up findings were seen as
supporting the possibility that VNS has clinically important
antidepressant effects, which formed the basis for this
double-masked, randomized, sham-controlled acute trial.
Specifically, we hypothesized that 10 weeks of VNS, as
opposed to 10 weeks of sham VNS, would result in a greater
proportion of responders based on a ⱖ50% reduction in
baseline HRSD24.
BIOL PSYCHIATRY 2005;58:347–354
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Methods and Materials
Participants
To participate in this study, participants had to have a current
DSM-IV (American Psychiatric Association 2000) primary diagnosis of major depressive disorder (MDD) or bipolar I or II
disorder (BPI or BPII). To ensure that the participants in the
study required long-term treatment, entrance criteria required
that participants be in the current major depressive episode
(MDE) for ⱖ2 years or to have had at least four lifetime major
depressive episodes, including their current MDE. The study
included men or women, aged 18 to 80 years. Women could not
be pregnant and had to use acceptable birth control methods
(including abstinence). The baseline score of the HRSD24 (average of two measures) had to be ⱖ20. Participants with bipolar
disorder had to be resistant to, intolerant of, or have a medical
contraindication to lithium.
Exclusionary criteria included atypical or psychotic features in
any MDE; lifetime history of any nonmood psychotic disorder
(e.g., schizophrenia); current rapid cycling bipolar disorder; or a
current secondary diagnosis of delirium, dementia, amnesia, or
other cognitive disorder (based on DSM-IV criteria). Participants
with clinically significant current suicidal intent and those with
certain risks related to the surgical implantation of the VNS
device were also excluded.
Treatment resistance was defined for the current MDE using a
modified Antidepressant Treatment History Form (ATHF) (Prudic
et al 1990, 1996; Sackeim 2001; Sackeim et al 1990). For the
current MDE, participants must have had an unsatisfactory
response to at least two adequate trials of different classes of
antidepressant medication, but not more than six, regardless of
antidepressant category based on participant/family interviews,
medical records, and, when available, pharmacy records. Trial
adequacy was defined by both the ATHF dose and duration
criteria for each medication trial. Each medication trial was
scored on a scale of 1 to 4 according to the Antidepressant
Resistance Rating (ARR) scale. An ARR score of ⱖ3 was required
to designate a trial as adequate. For example, acceptable trials of
fluoxetine or imipramine required at least 4 weeks of treatment at
a minimum dose of 20 or 200 mg/day, respectively. Medications
that could potentially receive a rating of 3 or higher, indicating an
adequate trial, were restricted to those with efficacy in the
treatment of a major depressive episode with either major
depressive or bipolar disorders, as supported by double-masked,
placebo-controlled trials. For all participants, the classes of
antidepressant treatments considered in determining the adequacy of trials included heterocyclics/tricyclics, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, bupropion, mirtazapine, nefazodone, trazodone, venlafaxine,
reboxetine, and electroconvulsive therapy (ECT). In addition, for
bipolar disorder, selected anticonvulsants (carbamazepine or
lamotrigine) or lithium given at a sufficient oral dose or at
sufficient serum concentration for an adequate duration could
constitute an adequate trial. Thus, across unipolar and bipolar
disorder, 11 classes of potentially adequate mood disorder
treatments could count towards the study inclusion criteria. In
addition, participants had to have shown no substantial response
to at least 6 weeks of psychotherapy during any MDE.
Study Overview
The study was conducted at 21 sites. The Institutional Review
Board at each site approved the study, which was performed
under an Investigational Device Exemption (IDE) from the Food
www.sobp.org/journal
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and Drug Administration (FDA) (see Acknowledgments). All
study participants signed written informed consent forms.
The participants completed a pre-implantation baseline period (up to 45 days) during which clinical assessments were
performed on two separate occasions. To qualify for device
implantation, participants had to score ⱖ20 (the average of the
two baseline measurements) on the 24-item Hamilton Rating
Scale for Depression (HRSD24) (Hamilton 1960, 1967; Moberg et
al 2001). Participants were not withdrawn from psychotropic
medications. Rather, participants maintained a stable medication
regimen for at least 4 weeks before the initial baseline visit, as
well as during baseline, recovery, and the 10-week acute phase
treatment period.
Device implantation was followed by a 2-week, singlemasked recovery period during which the VNS device remained
off to allow for surgical recovery. Participants were told that
stimulation might or might not be turned on immediately after
surgery. Many participants experience no sensations when the
device is operated at low stimulus intensity, or even at higher
intensities for some participants. These facts were communicated
to participants to help preserve the blind.
The study was a double-masked trial with 1:1 randomization
to sham VNS or active VNS. Those who received sham VNS were
offered active VNS after this trial (Rush et al, this issue). A third
party, independent from the investigators and any staff at the
study sites, served as the randomization agent. Participant numbers were assigned in sequence for all study participants, regardless of the randomization assignment. The device programmer
obtained the randomization assignment for each participant.
Participants had to score ⱖ18 on the HRSD24 at visit 2 (14 days
post-implantation) to enter the acute treatment phase. For the
active VNS group, the device was turned on after the 2-week
recovery period and the output current (mA setting) was increased progressively to the maximal level that could be comfortably tolerated by the participant. Stimulus parameters were
adjusted over the first 2 weeks (stimulation adjustment period)
following the recovery period, and clinical assessments were
performed weekly.
At 4 weeks post-implantation (i.e., after 2 weeks of stimulation initiation for the active VNS group), stimulation parameters
were fixed for the remaining 8 weeks of the acute study. While
a decrease in stimulation parameters was permitted if intolerable
side effects developed, no participant required such adjustments.
Participants were seen weekly for the next 2 weeks and then
every other week over the ensuing 6 weeks. This fixed-dose
stimulation period lasted 8 weeks. The total duration of stimulation was 10 weeks.
Identical procedures, including device implantation, were
followed with the sham VNS group. In this group, however,
the device was not turned on. The unmasked device programmer made all adjustments in stimulation parameters, including
the sham adjustments. This person was not involved in any
participant care or clinical assessments. The participants,
outcome raters, and all other staff involved in clinical care and
management were masked to whether or not VNS was active
or sham. To preserve the mask to the raters, the unmasked
programmer turned off the device at all clinic visits to prevent
the occurrence of voice alterations should stimulation occur
during the clinical assessment. The unmasked device programmer collected information on all adverse events, and, to
further ensure masking, patients were scheduled to avoid
overlap in the waiting room.
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VNS Treatment
The device implantation procedures and protocol-recommended treatment parameters were identical to those used in the
studies for patients with pharmacoresistant epilepsy (Ben-Menachem et al 1994; Handforth et al 1998; Vagus Nerve Stimulation
Study Group 1995) and in the open trial for patients with TRD
(Sackeim et al 2001a). At each clinic visit, accuracy of stimulation
parameters was verified, and the details of each stimulation
occasion since the last visit were downloaded into a database
stored on the VNS therapy system portable computer.
For the active VNS group, the protocol called for 20 Hz, 500
s pulse width, and on/off cycle of 30 sec on and 5 min off
during the 2-week stimulation adjustment and acute phase trial
period. The output current, beginning at .25 mA as the lowest
dose, was increased gradually (in .25 mA increments) until a
comfortable level was reached. Once this level was attained,
participants left the clinic with the VNS device programmed at
those settings. Additional increases (in .25 mA steps) could be
made up to 3.5 mA at any time during the stimulation adjustment
period over the next 2 weeks.
Concomitant Therapy
Participants could be taking up to a total of five antidepressant, mood stabilizer, or other psychotropic medications (e.g.,
atypical antipsychotics), provided the medication type and dosage were kept stable throughout the baseline period and
throughout the 12 weeks after implantation. Specifically, medication dosage could not be increased during this acute trial. The
only psychotropic medication that could be added during the
trial was trazodone (up to 300 mg/day), for insomnia, as needed.
Concomitant ECT, investigational drugs, or treatment with another investigational device was not permitted.
Evaluations and Outcome Measurements
Baseline evaluations included medical and psychiatric history,
physical and neurological exams, and pre-surgical laboratory
tests. Efficacy and safety data were gathered at the two baseline
visits and at post-implantation weeks 1 and 2 (recovery period),
weeks 3 and 4 (stimulation adjustment period), and weeks 5, 6,
8, 10, and 12 (fixed-dose stimulation period). Clinical assessments of depressive symptoms included the HRSD28 (Hamilton
1960, 1967; Moberg et al 2001) using a semistructured interview
(Williams 1988) and the 10-item Montgomery-Äsberg Depression
Rating Scale (MADRS) (Montgomery and Asberg 1979). Although
the 28-item HRSD was administered to participants, the total of
the first 24 questions was used to define the HRSD24 total score.
Thus, HRSD24 results are reported for the study participants. The
HRSD24 includes the HRSD21 (Hamilton 1960, 1967) plus three
additional items: 1) hopelessness, 2) helplessness, and 3) worthlessness. Thus, the HRSD24 includes the first 24 items of the
HRSD28. The 30-item Inventory of Depressive Symptomatology –
Self-Report (IDS-SR30) (Rush et al 1996, 2000a; Trivedi et al 2004;
Rush et al, this issue) was used to measure self-reported depressive symptoms. Manic/hypomanic symptoms were rated by the
Young Mania Rating Scale (YMRS) (Young et al 1978). The
emergence of significant hypomania or mania was defined a
priori as a score ⱖ15 on the YMRS. In such cases, the DSM-IV
criteria for mania were applied to declare the presence or
absence of mania. The Clinical Global Severity (CGI-S) and
Improvement (CGI-I) ratings (Guy 1976) were used to assess
overall symptom severity and change. Functional outcomes (or
quality of life) were assessed using the Medical Outcomes Study
Short Form-36 (MOS SF-36) (Ware and Sherbourne 1992).
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To assess inter-rater reliability, HRSD24 interviews were videotaped at key time points, including baseline and acute phase
termination, and 6-, 12-, and 18-month follow-up. Over the
course of the study, a random subset of these interviews were
sent to the New York State Psychiatric Institute/Columbia University (New York, New York) for independent, time- and
site-masked ratings. Expert clinical evaluators who were masked
to treatment condition, time point in treatment or follow-up, and
the HRSD24 scores obtained at the site, scored 379 of these
interviews.
The HRSD24 assessments used a semi-structured interview
guide adapted from Williams (1988) that provided a set of initial
and follow-up questions for each item. The order of items was
invariant and the descriptive anchors provided for each item
addressed the ambiguities in the brief descriptions provided by
the original HRSD24. Conventions for HRSD24 scoring were
provided in the manual. To contribute ratings in the study, the
clinical evaluators at each site had to pass a certification process.
Certification involved achieving a strong level of reliability with
consensus expert scores in rating a set of five practice tapes.
Furthermore, each site rater was videotaped while using the
semi-structured interview to conduct HRSD24 assessments of
three patients. These tapes were evaluated for adequacy by
expert clinical evaluators at the New York State Psychiatric
Institute.
Adverse events and concomitant medications were coded
using the COSTART (Coding Symbols for Thesaurus of Adverse
Reaction Terms) (Food and Drug Administration 1995) dictionary.
Statistical Methods
Quintiles Inc. (Research Triangle Park, North Carolina), a
clinical research organization (CRO), primarily conducted clinical monitoring visits at the 21 sites. Data were entered, verified,
and analyzed using procedures that ensured the accuracy of the
data and results. The primary outcome measure was the categorical classification of response, defined a priori as a ⱖ50%
reduction after 10 weeks (LOCF) relative to the mean HRSD24
score obtained at the two baseline (pre-implantation) visits. The
sample size was powered to detect a difference in the HRSD24
response rate of approximately 17%. For secondary outcome
measures, response was defined as a ⱖ50% reduction in the
average of the two baseline scores for the MADRS or IDS-SR30, or
a CGI-I score of 1 or 2 (much or very much improved). Evaluable
participants in the sham and active VNS treatment groups were
compared in response rates with Mantel-Haenszel chi-square
tests stratifying by pooled investigator site. Treatment groups
were also compared for average percent improvement from
baseline in HRSD24, MADRS, IDS-SR30, SF-36, and YMRS scores
via analyses of covariance (ANCOVA) adjusting for baseline
value and pooled investigator site. A repeated measures linear
regression analysis was used to compare differences in outcome
between the sham group and the active group. Demographic and
clinical features of the sham VNS group were compared with
those of the active VNS group with ANOVAs adjusting for pooled
investigator site, and Mantel-Haenszel chi-square tests stratified
by pooled investigator site, or Fisher’s exact test, as appropriate.
Sites were pooled prior to unblinding into four groups for
statistical adjustment, such that sites enrolling a similar number of
participants were combined in the same pooled site. Statistically
significant p-values were considered to be ⱕ.050. Inferential
conclusions regarding VNS effectiveness in this study were
limited to the single a priori primary outcome (HRSD24 rewww.sobp.org/journal
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Table 1. Baseline Demographics and Clinical Features
Parameter
% Female
% Caucasian
Age (mean, SD) (yrs)
Median (range) (yrs)
% with Recurrent MDD
% with Single-episode MDD
% Bipolar I
% Bipolar II
Duration of Current MDE (mos) (mean, SD)
Median (range) (mos)
Age at Onset of First Depression Symptoms (yrs.)
Duration of Illness (mean, SD) (yrs.)
Median (range) (yrs.)
Lifetime MDEs (%)
ⱕ2
3–5
6–10
⬎10
Unknown
Lifetime Hospitalizations (mean, SD)
Median (range)
% Receiving ECT (current MDE)
% Receiving ECT (lifetime)
HRSD24 (BL) (mean, SD)
MADRS (BL) (mean, SD)
IDS-SR30 (BL) (mean, SD)

Treatment (n ⫽ 112)

Control (n ⫽ 110)

Total (n ⫽ 222)

59
97
47.0 (9.0)
47.0 (24–72)
81.3
7.1
5.4
6.3
46.6 (51.3)
32.5 (4–354)
21.9 (11.0)
26.1 (11.0)
26.5 (4–48)

66
96
45.9 (9.0)
47.0 (24–68)
74.5
16.4
3.6
5.5
51.7 (52.2)
34.0 (2–245)
22.1 (12.5)
24.9 (13.0)
25.0 (3–57)

63
96
46.5 (9.0)
47.0 (24–72)
77.9
11.7
4.5
5.9
49.1 (51.7)
33.5 (2–354)
22.0 (11.7)
25.5 (12.0)
25.0 (3–57)

22
39
24
8
6
2.9 (6.6)
1.0 (0–64)
33.0
51.8
28.8 (5.3)
31.4 (6.3)
44.3 (9.1)

26
28
29
14
4
2.3 (3.6)
1.0 (0–20)
38.2
53.6
29.7 (5.2)
31.9 (6.3)
45.4 (8.5)

24
34
27
11
5
2.6 (5.3)
1.0 (0–64)
35.6
52.7
29.2 (5.3)
31.7 (6.3)
44.8 (8.8)

MDD, major depressive disorder; MDE, major depressive episode; ECT, electroconvulsive therapy; HRSD24, 24-item Hamilton Rating Scale For Depression;
BL, ; MADRS, Montgomery-Åsberg Depression Rating Scale; IDS-SR30, Inventory of Depressive Symptomatology-Self-Report.

sponse). We interpreted all p-values from secondary outcomes as
descriptive in nature; no adjustments were made for multiple
comparisons.

Results
Sample Characteristics
Of the 266 participants enrolled in the trial, 235 participants
were implanted. Altogether, 21 sites enrolled from four to 22
participants (mean 12.7; median 13), with only five sites enrolling
fewer than 10 participants. Thirty-one enrolled participants were
discontinued before implantation because they did not meet
eligibility criteria (n ⫽ 13) or withdrew consent (n ⫽ 18). Of 235
implanted participants, 13 participants were not evaluable for
efficacy: four did not meet eligibility criteria for continuing in the
acute trial after implantation (their HRSD24 scores were ⬍ 18),
and nine had protocol violations after randomization (e.g.,
medication additions in violation of the requirement for a stable
medication regimen). Thus, 222 participants are included in the
efficacy analysis, with 112 participants randomized to the active
VNS group and 110 randomized to the sham VNS group.
Demographic data are reported on the 222 evaluable participants, and safety findings are reported on the total 235 implanted
participants. Only three of the 235 participants (all in the VNS
active stimulation group) withdrew from the study because of
AEs, and one of the participants who withdrew did so at the end
of the study. Table 1 presents the clinical and demographic
features of the evaluable sample (n ⫽ 222). No statistically
significant differences were noted in the clinical and demographic features between the active and the sham groups.
On average, participants in both groups had received over 16
unique mood disorder treatments before they entered the study,
www.sobp.org/journal

and had tried more than nine such medications during the
current MDE. From a lifetime perspective, 89% had been treated
with fluoxetine, 89% with bupropion, and 88% with venlafaxine.
Prior treatments (lifetime and current MDE) were similar for the
active VNS and sham VNS groups. Over half (53%) of the
evaluable sample had a history of ECT, and 36% had received
ECT during the current MDE.
Table 2 shows the distribution of ATHF-defined adequate
treatment trials in the current MDE. The active and sham VNS
groups did not differ in the mean and distributions of the number
of adequate trials during the current MDE (p ⫽ .5020, CochranMantel-Haenszel).
Table 3 summarizes the treatments being taken in addition to
VNS during the acute phase trial. The minor differences in the
frequency of use of any of the concomitant treatments between
the active and sham groups were not clinically meaningful.
Table 2. Percent of Participants with Various Degrees of Treatment
Resistance
Number of Unsuccessful
ATHF Treatmentsa

Treatment
(n ⫽ 112)

Control
(n ⫽ 110)

Total
(n ⫽ 222)

2
3
4
5
6b

30.4%
23.2%
20.5%
17.0%
9.0%

31.8%
28.2%
18.2%
12.7%
9.1%

31.1%
25.7%
19.4%
14.9%
9.0%

ATHF, Antidepressant Treatment History Form.
a
Unsuccessful ATHF treatment refers only to treatments rated on ATHF
for the current major depressive episode.
b
One participant in the treatment group had failed 7 ATHF treatments.
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Table 3. Concomitant Mood Disorder Treatments During the Acute Phase
Triala
Category of Treatment
Heterocyclics/TCAs
SSRIs
MAOIs
Anticonvulsants—total
(carbamazepine, lamotrigine,
valproic acid, gabapentin,
topiramate, tiagabine)
Stimulants
Atypical Antipsychotics
Non atypical Antipsychotics
Anxiolytics
Specific Medications of Interest
Bupropion
Venlafaxine
Mirtazapine
Nefazodone
Trazodone
Lithium

Treatment
(n ⫽ 112)

Control
(n ⫽ 110)

Total
(n ⫽ 222)

10%
46%
6%
30%

14%
44%
7%
33%

12%
45%
6%
31%

20%
26%
0%
65%

22%
24%
6%
50%

21%
25%
3%
57%

27%
26%
15%
14%
17%
15%

18%
29%
11%
6%
14%
7%

22%
27%
13%
10%
16%
11%

TCA, tricyclic antidepressant; SSRI, selective serotonin reuptake inhibitor; MAOI, monoamine oxidase inhibitor.
a
The differences between the treatment and control groups were not
found to be statistically significant for categories of treatment (2 ⫽ 9.40; df
⫽ 7) or specific medications of interest (2 ⫽ 5.49; df ⫽ 5).

Efficacy
VNS Parameters. Median output current at the last recorded
visit was .75 mA (range, .00 to 1.50 mA) and the average output
current was .67 mA (SD ⫽ .33). Of the 111 evaluable participants
with values recorded at study exit, 53 (48%) received ⱕ.50 mA
and 58 (52%) received ⬎ .50 mA output current. Median signal
frequency was 20 Hz (range, 10 to 20 Hz), median pulse width
was 500 sec (range, 130 to 500 sec) median on time was 30 sec
(range, 14 to 30 sec), and off time was 5 min. For the HRSD24
scores, the intraclass correlation coefficent (ICC, single rater)
across the 379 interviews was .94, indicating high inter-rater
reliability for the HRSD24 scores. No site showed poor reliability
as the ICC value computed per site ranged from .87 to .98, with
a median of .95. The average discrepancy between the original
ratings at each site and those of the Columbia University rater,
while statistically significant (df ⫽ 378, t ⫽ 5.08, p ⬍ .001), was
slight and reflected the original raters scoring the patients .78
points higher on the HRSD24 than the Columbia rater (Original
rater: 23.90 ⫾ 8.74; Columbia rater: 23.12 ⫾ 8.33). The magnitude
of the discrepancies between the two sets of raters (both
directional and absolute) did not differ among the sites.
Table 4 summarizes the LOCF outcomes for the efficacy
evaluable sample (n ⫽ 222). Response rates were generally
similar across sites, although some variation was seen (seven
sites had ⬍ 10% response rate, four sites had ⱖ 25% response
rate). Figure 1 shows the response rates by HRSD24 and IDS-SR30
using the LOCF sample. The difference in the HRSD24 response
rates was not significant (chi-square ⫽ 1.32, df ⫽ 1, p ⫽ .251), but
the difference in the IDS-SR30 response rates was statistically
significant (chi-square ⫽ 4.62, df ⫽ 1, p ⫽ .032). Two other
secondary measures of efficacy were not statistically significant,
the MADRS (chi-square ⫽ .778, df ⫽ 1, p ⫽ .378) and the CGI-I
(chi-square ⫽ .208, df ⫽ 1, p ⫽ .648).
A repeated measures linear regression analysis was performed for the evaluable sample for raw scores of the active

Table 4. Clinical Outcomes for VNS versus Sham (at 10 weeks LOCF)
Rating
HRSD24 Response Rate (%)
MADRS Response Rate (%)c
CGI-I Response Rate (%)d
IDS-SR30 Response Rate (%)e
HRSD24 % Improvement from
Baseline (mean, SD)
MADRS % Improvement from
Baseline (mean, SD)
IDS-SR30 % Improvement from
Baseline (mean, SD)

Treatment
(n ⫽ 112)
15.2%
15.2%
13.9%
17.0%

Control
(n ⫽ 110)

p

10.0%
11.0%
11.8%
7.3%

.25a
.378
.648
.032b

16.3 ⫾ 28.1

15.3 ⫾ 25.5

.639

17.1 ⫾ 31.2

12.4 ⫾ 27.1

.208

21.2 ⫾ 25.4

16.3 ⫾ 26.2

.158

VNS, vagus nerve stimulation; LOCF, last observation carried forward;
HRSD24, 24-item Hamilton Rating Scale for Depression; MADRS, Montgomery-Åsberg Depression Rating Scale; CGI-I, Clinical Global Improvement ratings; IDS-SR30, 30 item Inventory of Depressive Symptomalogy-Self-Report.
a
Primary outcome.
b
Statistically significant secondary parameter.
c
One patient in the control group did not have a MADRS assessment
completed during the study.
d
One patient in the treatment group and one patient in the control
group did not have a CGI assessment completed during the study.
e
One patient in the control group did not have an IDS-SR30 assessment
completed during the study.

versus sham groups. At 12 weeks, the estimated difference for
the HRSD24 was –.769, SE .80, 95% CI (-2.34, .80), p ⫽ .336 and
the estimated difference for the IDS-SR was –2.374, SE 1.23, 95%
CI (⫺4.78, .03), p ⫽ .053.
The active and sham VNS groups did not differ on either
physical or mental component of the MOS-SF36. For the physical
component, mean change was –.9 (SD ⫽ 8.3) for the VNS group
(n ⫽ 107) and –1.6 (SD ⫽ 8.4) for the sham group (n ⫽ 107; F ⫽
.50, df ⫽ [1, 208], p ⫽ .480, ANCOVA). For the mental component, mean change was 5.0 (SD ⫽ 11.6) for the VNS group (n ⫽
107) and 4.0 (SD ⫽ 10.2) for the sham group (n ⫽ 107; F ⫽ .69,
df ⫽ [1, 208], p ⫽ .406, ANCOVA).
Adverse Events
Two participants, both in the active VNS group, did not
complete the acute study because of adverse events (AEs). One

Figure 1. Between Group last observation carried forward (LOCF) Responder Rates (HRSD24 and IDS-SR30) (n ⫽ 222). HRSD24, 24-item Hamilton
Rating Scale for Depression; IDS-SR30, Inventory of Depressive Symptomatology – Self-Report; VNS, vagus nerve stimulation. * Primary outcome; **
Secondary outcome.
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participant underwent device explantation due to infection. The
second participant committed suicide after 5 weeks of VNS
treatment, which, in the opinion of the investigator, was most
likely due to the underlying mood disorder and not study
participation. At the end of the study, a third participant withdrew because of hoarseness.
Overall (Table 5), the AEs encountered were similar to those
of the prior study of VNS for treatment-resistant depression
(TRD) (Sackeim et al 2001b) and for epilepsy (Morris and Mueller
1999). The most common AE was voice alteration. Of 30 total
serious adverse events (SAEs) involving 27 participants, 16 SAEs
occurred in the active VNS group and 14 in the sham group. This
total included 12 SAEs involving 11 participants of worsened
depression that required hospitalization (seven participants in
sham, four participants in active VNS, and one participant who
had not yet received stimulation, but who was assigned to the
active VNS group). One case of asystole and one case of
bradycardia, both during surgery, occurred in the active VNS
group, while neither occurred in the sham group. No other
cardiac SAEs occurred during study treatment. The randomized
groups had no meaningful differences in change from baseline
for temperature, heart rate, diastolic or systolic blood pressure, or
in weight (active VNS lost an average of 1.2 ⫾ 8.0 lb; sham VNS
lost an average of 2.1 ⫾ 8.7 lb).
Two participants in the active VNS group (one of whom had
a diagnosis of bipolar I disorder at baseline) met the threshold of
significant hypomania or mania, a score ⱖ15 on the YMRS,
which was validated by DSM-IV criteria. Neither participant
underwent VNS dose reduction or discontinued VNS. These
elevated YMRS scores occurred at initiation of stimulation for one
participant and 8 weeks of VNS for the other. Both resolved
spontaneously after 1 to 2 weeks.

Discussion
This trial is the first sham-controlled, acute-treatment study to
be conducted in such a chronically ill, treatment-resistant depressed population characterized by high rates of prior ECT
(53%), prior hospitalization (63%), and substantial disability
(SF-36 Mental Score of approximately 27 out of a possible 100
points). Depressed patients seen in general practice scored 46.3
in the Medical Outcomes Study (Komaroff et al 1996). This study
did not yield definitive evidence of short-term efficacy in the
context of this chronically ill, treatment-resistant, depressed
Table 5. Percent of Participants (n ⫽ 235) Reporting Adverse Eventsa
Adverse Event
Voice Alteration
Cough Increased
Dyspnea
Dysphagia
Neck Pain
Paresthesia
Vomiting
Laryngismus
Dyspepsia
Wound Infection
Palpitations

VNS Group
(n ⫽ 119)

Sham Control Group
(n ⫽ 116)

68%
29%
23%
21%
21%
16%
11%
11%
10%
8%
5%

38%
9%
14%
11%
10%
10%
5%
2%
5%
2%
3%

VNS, vagus nerve stimulation.
a
All adverse events occurring in ⱖ5% of participants receiving stimulation and 1.5⫻ sham control group are listed whether or not related to
stimulation or implantation.
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population. This trial revealed that A) VNS was well tolerated; B)
the adverse event profile and AE rates closely approximated
those seen in patients with epilepsy; C) the modest difference in
response rates to active VNS (15.2%), and sham VNS group
(10.0%) was not statistically significant for the HRSD24, the
primary measure, and D) the secondary measure, the IDS-SR30
revealed a significant difference favoring VNS over sham (analyzed without correction for multiple tests). Importantly, only a
10% placebo (sham) response was found in this rarely studied
population. These findings indicate either that VNS is ineffective
(at least in the short run), or that this study could be a failed trial
because of a variety of issues including: (1) study design, (2)
study sample, and (3) treatment delivery.
Study Design
The sample size was powered to detect a difference of
approximately 17% between placebo response and treatment
response. The HRSD24 response rate was 15.2% (17/112, LOCF)
for participants in the active VNS group and 10.0% (11/110) for
those in the sham group. We could have simply underpowered
the study, having assumed a better response rate than was
obtained after the 10 weeks of VNS.
Although 10- to 12-week acute studies for regulatory approval
are common for studies of depression, studies of TRD are less
common, and longer acute-phase studies may be necessary in
TRD populations (Rush et al 2003b). Naturalistic follow-up
studies of both VNS-treated epilepsy patients (DeGiorgio et al
2000; Morris and Mueller 1999) and TRD patients (Marangell et al
2002) suggest that the effect of VNS may increase after the acute
phase. If more time is needed for VNS benefits to become
evident in this TRD group, a longer randomized controlled trial
might have produced positive findings as suggested by the
longer-term, follow-up data on this cohort (Rush et al, this issue),
as well as a comparison with a benchmark control group
(George et al, this issue).
Only 25 of the 235 enrolled participants were classified as
bipolar I or II. Of the 222 participants in the evaluable LOCF
sample, 23 participants were classified as bipolar. These participants with bipolar disorder had a response rate of 8.7% (2/23) as
compared with those with MDD 13.1% (26/199) as graded by the
HRSD24. Thus, inclusion of bipolar depressed participants did
not likely affect results.
Study Sample
The study design was nearly identical to the Sackeim et al
(2001b) design, except that the degree of allowable treatment
resistance was capped at ⱕ6 antidepressant trials from different classes during the current MDE. However, the overall
mean duration of illness (time from the onset of the first mood
episode to study entry) was greater in the present study than
for the Sackeim et al (2001b) group (25.5 vs. 18.1 years), and
the present study had fewer participants with bipolar disorder
(10.4% versus 27.0%). The duration of the current episode in
the present study was much shorter (4.1 years versus 9.9 years;
median 2.8 years vs. 6.6 years) than the Sackeim et al (2001b)
group.
These data argue that the degree of lifetime treatment resistance among participants in the present study was likely not
lower than for the Sackeim et al (2001b) study, and was
potentially higher. Because greater treatment resistance is associated with lower acute response rates in ECT (Sackeim et al
1990), in mood stabilizers among patients with bipolar disorder
(Barbee and Jamhour 2002), and in VNS (Sackeim et al 2001b), a
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potentially higher treatment resistance would be expected to
reduce response rates for 10 weeks of VNS.
Treatment Delivery
Although no direct evidence links the amount of current
delivered during VNS with the outcome in depression, the
average output current in the epilepsy studies was 1.3 mA for
patients who received active VNS (Handforth et al 1998). In
Sackeim et al (2001b), the median output current was .75 mA
(range, .25 mA to 3.0 mA), and the average was .96 mA (SD ⫽
.54 mA). In the present study, the median output current at the
last recorded visit was .75 mA (range, .00 to 1.50 mA) and the
average output current was .67 mA (SD ⫽ .33). Of the 111
evaluable participants with values recorded at study exit, 53
(48%) received ⱕ.50 mA and 58 (52%) received ⬎.50 mA
output current. The use of lower output current settings in this
study could be attributed to several factors. Data from the
Sackeim et al (2001b) study did not indicate that higher output
currents were associated with a better response. Thus, the
need to push the output current to the maximally tolerated
dose was not established at the time of this study, and, indeed,
it may not be necessary. The need to maintain the blind was
not a factor in the Sackeim et al (2001b) trial. However, in the
present study, the desire to protect the blind may have limited
the number of opportunities that were provided to adjust the
dose for tolerability. An exploratory analysis of this acute
study found no relationship between output current and the
percentage of change in the HRSD24. Theoretically, the lower
output current settings used in this study could have limited
the acute response rates, though the actual differences in
dosage are modest. Furthermore, the current study had similar
rates of adverse events as reported in the Sackeim et al
(2001b) study, suggesting that the VNS dose (current) was
pushed to at least the same degree of tolerability as in the
Sackeim et al (2001b) study.
In sum, VNS was safe and well tolerated. This study did not
yield definitive evidence of short-term efficacy for adjunctive
VNS in treatment-resistant depression. By all measures, VNS was
associated with greater symptom reduction. In the primary
analysis, HRSD24, the response rate was 15.2% in the active
treatment group and 10.0% in the sham group, a modest difference that was not statistically significant. A secondary outcome,
the IDS-SR30, which revealed a significantly greater response rate
with VNS (17.0%) than with sham (7.3%), was not corrected for
multiple comparisons. Whether study design, study sample, or
stimulation parameters contributed to this failed acute-phase trial
is unclear. Alternatively, this acute phase trial may simply have
failed because VNS is not effective in reducing the symptoms of
depression. Given the 25-year history of depression and substantial degree of treatment resistance of these participants, longer
treatment with VNS may be necessary to achieve clinically
meaningful benefit (Rush et al, this issue).
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